Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders

BACKGROUND: Retinoid‐based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non‐specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may address these shortcomings. OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Veit, J.G.S., Poumay, Y., Mendes, D., Kreitinger, J., Walker, L., Paquet, A., Menigot, C., Zolezzi, F., Paller, A.S., Diaz, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060145/
https://www.ncbi.nlm.nih.gov/pubmed/35664983
http://dx.doi.org/10.1002/ski2.22

Ejemplares similares

Ejemplares similares